CYP cynata therapeutics limited

9.68%

17.0¢

To CYPs credit, they are starting the trial before second line...

First 1608 Last

Share
Profile

Follow
Bazsa

4,161 Posts.

1467

12/12/22

20:36

Post #: 65283697
Share

Originally posted by JB1975: ↑

I agree with the main thrust of your comment. Yes placebo plus standard of care (being corticosteroids) is control. And yes it would be a harder sell to take the trial with a one in three chance of getting the control arm if MSB had approval by then.

But MSB can't get a BLA approval until it makes a formal BLA submission and it seems its not planning to do that until it gets feedback from the FDA/CBER on the data its already sent in - a strategy I agree with by the way - its less risky but will take longer - but the FDA/CBER may take quite a while to respond to the IND file update - and what is most to the point is that they may not think what they've been given is enough to satisfy the CRL.

In one of my recent posts on MSB there is a link to a paper from 2021 by Klinker and Bauer that looks at potency assays and specifically priming of MSC lines. They find INF-gamma to be more influential than TNF-alpha (which acts through the TNFR1) on t cell proliferation inhibition - but they also find TNF-alpha adds in a synergistic way to what INF-gamma priming does.

The problem I see for MSB is that they've never reported measuring INF-gamma in a potency assay.

MSB's ODAC slides CC-15 and CC-22 show INF-gamma involvement so they recognize its possible importance but they don't report measuring or tracking it anywhere.

In my opinion Bauer and Klinker and others at CBER are going to, based on their own research, think the TNFR1 expression and IL-2Ralpha inhibition may not be capturing the key potency factors in the medicines that MSB is producing.

All MSBs longevity data, the good results comparatively for four years come from three donors that provided cells to the 54 patient trial. Those three donors might have had cellls that were effective because of INF-gamma handling not just or TNFR1 handling but that doesn't appear to have been measured anywhere. This matters because MSB will not be able to keep using the same three donors - they'll need new ones and unless they have potency assays that can be shown to be potency predictors there isn't a way to show the new batches will be potent.

INF-gamma doesn't operate through the TNFR1 pathway. It inhibits t cell proliferation another way through IDO and it doesn't seem to be something that MSB is capturing in its potency assays.

All above is my opinion. I think it less than an even money chance that CBER can agree that MSBs existing data (what MSB have provided and said they have provided) is sufficient to predict future potency even though they may agree that MSBs 54 patient trial seems to have worked.

Expand

To CYPs credit, they are starting the trial before second line treatments are considerd. So both arms would still have second line treatments available if required. This would include Remestemcel if available. They would be considerd to have failed the endpoint.

The problem is that this is not the only trial in the same population

CYP Price at posting: 30.5¢ Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

AII

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

First 1608 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 17.0¢		Change 0.015(9.68%)		Mkt cap ! $38.41M

Open	High	Low	Value	Volume
15.5¢	17.0¢	15.5¢	$47.10K	289.1K

Buyers (Bids)

No.	Vol.	Price($)
1	50000	16.5¢

Sellers (Offers)

Price($)	Vol.	No.
17.0¢	23813	3

View Market Depth

No.	Vol.	Price($)
1	50000	0.165
4	47240	0.155
4	161673	0.150
1	5000	0.145
2	45000	0.140

Price($)	Vol.	No.
0.170	18813	2
0.175	55250	1
0.180	62619	3
0.185	35990	1
0.195	19300	1

Last trade - 16.10pm 27/06/2025 (20 minute delay)

CYP (ASX) Chart

To CYPs credit, they are starting the trial before second line...

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Australia’s gas crisis is here – and dying coal plants aren’t helping

Monash IVF shares cater 25% – Disaster or deep-value play?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

To CYPs credit, they are starting the trial before second line...

Top Stories

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Australia’s gas crisis is here – and dying coal plants aren’t helping

Monash IVF shares cater 25% – Disaster or deep-value play?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News